Recon: FDA approves Keytruda as adjuvant for NSCLC; Philips to cut 6,000 more jobs after Q4 losses
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy